JBIO

Jade Biosciences Inc. (JBIO)

Market Closed

16 Jun, 20:00

NASDAQ (CM)

6. 99

+0.23

+3.4%

- Market Cap

- P/E Ratio

- Div Yield

327,100 Volume

- Eps

$ 6.76

Previous Close

Day Range

6.61 7.25

Year Range

6.57 105

Want to track JBIO and more in your Portfolio? 🎯

Get Started For Free

Summary

JBIO closed Monday higher at $6.99, an increase of 3.4% from Friday's close, completing a monthly decrease of -3.45% or $0.25. Over the past 12 months, JBIO stock lost -92.55%.

JBIO pays dividends to its shareholders, with the most recent payment made on Apr 28, 2025. The next estimated payment will be in 1 month ago on Apr 28, 2025 for a total of $2.4.

The last earnings report, released on May 19, 2025, missed the consensus estimates by -3.04%. On average, the company has fell short of earnings expectations by -3.04%, based on the last three reports.

The stock of the company had never split.

The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

Overview
Earnings
News

JBIO Chart

Loading, please wait...

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a differentiated pharmacokinetic and pharmacodynamic profile with deep and sustained IgA reductions and the potential to support convenient subcutaneous dosing every eight weeks or longer First-in-human trial expected to begin second half 2025; biomarker-rich interim data in healthy volunteers expected first-half 2026 to inform patient dose and schedule Company to host conference call and webcast today, June 9, 2025, at 8:00 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy (IgAN), a chronic autoimmune kidney disease.

Globenewswire | 1 week ago

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025. The presentation, titled “Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN,” will be delivered during the Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases.

Globenewswire | 2 weeks ago